

ATTORNEYS AT LAW



Robert Greene Sterne Edward J. Kessler Jorge A. Goldstein David K.S. Cornwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee Steven R. Ludwig John M. Covert Linda E. Alcom Robert C. Millonig Donald J. Featherstone Timothy J. Shea, Jr Michael V. Messinger Judith U. Kim Patrick E. Garrett Jeffrey T. Helvey Heidi L. Kraus Eldora L. Ellison Thomas C. Fiala Donald R. Banowit Peter A. Jackman Jeffrey S. Weaver Kendrick P. Patterson Vincent L. Capuano Brian J. Del Buono Virgil Lee Beaston Theodore A. Wood Elizabeth J. Haanes Joseph S. Ostroff Frank R. Cottingham Rae Lynn P. Guest Daniel A. Klein Jason D. Eisenberg Michael D. Specht Tracy L. Muller Jon E. Wright LuAnne M. DeSantis Ann E. Summerflich Helene C. Carfson Cynthia M. Bouchez Timothy A. Doyle Gaby L. Longsworth Lori A. Gordon Nicole D. Dretar Ted J. Ebersole Laura A. Vogel Bryan S. Wade Aaron L. Schwartz Shannon A. Carroll

Wesley W. Jones* Matthew E. Kelley* Michelle K. Holoubek* Marsha A. Rose*

Registered Patent Agents
Karen R. Markowicz
Nancy J. Leith
Matthew J. Dowd
Kattina Yujian Pel Quach
Bryan L. Skelton
Robert A. Schwartzman
Teresa A. Colella
Victoria S. Rutherford
Simon J. Elliott
Julie A. Heider
Mita Mukherjee
Scott M. Woodhouse

Christopher J. Walsh Liliana Di Nola-Baron Peter A. Socarras Jeffrey Mills Danielle L. Lettino

Of Counsel Kenneth C. Bass III Marvin C. Guthrie

*Admitted only in Maryland

*Admitted only in Virginia

*Practice Limited to

Federal Agencies

February 1, 2006

WRITER'S DIRECT NUMBER: (202) 772-8846 INTERNET ADDRESS: PCALVO@SKGF.COM

Art Unit 1646

Attn: Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Utility Patent Application

Application No. 09/475,158; Filed: December 30, 1999

For: PTH Functional Domain Conjugate Peptides, Derivatives
Thereof and Novel Tethered Ligand-Receptor Molecules

Inventors:

GARDELLA et al.

Our Ref:

0609.4780001/SRL/PAC

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Second Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(d);
- 2. One page of Form PTO/SB/08B listing two documents (AR13 and AS13);
- 3. Copies of documents AR13 and AS13 as listed on Form PTO/SB/08B;
- 4. Credit Card Payment Form (PTO-2038) in the amount of \$180.00 to cover the fee under 37 C.F.R. § 1.17(p) for the submission of the Information Disclosure Statement; and
- 5. Return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLLC : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents February 1, 2006 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

al A. Calio

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Paul A. Calvo

Agent for Applicants Registration No. 57,913

SRL/PAC/dbj Enclosures

491748_1.DOC

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

GARDELLA et al.

Appl. No.: 09/475,158

Filed: December 30, 1999

For: PTH Functional Domain

Conjugate Peptides, Derivatives Thereof and Novel Tethered Ligand-Receptor Molecules Confirmation No.: 6018

Art Unit: 1646

Examiner: Ruixiang Li

Atty. Docket: 0609.4780001/SRL/PAC

Second Supplemental Information Disclosure Statement Filing Under 37 C.F.R. § 1.97(d)

Mail Stop Amendment

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO/SB/08B are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this Second Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' First Supplemental Information Disclosure Statement filed on December 13, 2002 in connection with the above-captioned application. Copies of the documents are submitted.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached Form PTO/SB/08B based on information presently available to the undersigned. However, the listed

02/02/2008 SZEUDIE1 00000074 09475158

01 Fue:608 180.00 OP

publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Enclosed find our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p); in addition:

Statement under 37 C.F.R. § 1.97(e)(1). I hereby state that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. § 1.97(e)(1).

It is respectfully requested that the Examiner initial and return a copy of the enclosed Form PTO/SB/08B, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Paul A. Calvo

Agent for Applicants Registration No. 57,913

al A. Calw

Date: Feb. 1, 2006

1100 New York Avenue, N.W. Washington, D.C. 20005-3934 (202) 371-2600

491509_1.DOC

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 3651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

APPROVED TO SERVICE A PROVINCE OF THE P

Substitute for form 1449/PTO				Complete if Known		
CECOND	CLIDDI	100.410	NICE A T	Application Number	09/475,158	
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE				Filing Date	December 30, 1999	
				First Named Inventor	Thomas J. GARDELLA	
STATEMENT BY APPLICANT (Use as many sheets as necessary)				Art Unit	1646	
				Examiner Name	Ruixiang Li	
Sheet	1	of	1	Attorney Docket Number	0609.4780001/SRL/PAC	

-		NON PATENT LITERATURE DOCUMENTS	
Initials* No. the item (book, magazine, journal, serial, symposium, catalog, etc.), d		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	AR13	Iwakura, M. and Nakamura, T., "Effects of the length of a glycine linker connecting the N-and C-termini of a circularly permuted dihydrofolate reductase," <i>Protein Engineering</i> 11:707-713, Oxford University Press (August 1998)	.c = 777 (H 5 = 585
	AS13	Tsomaia, N., et al., "Cooperative Interaction of Arginine-19 and the N-Terminal Signaling Domain in the Affinity and Potency of Parathyroid Hormone," Biochem. 43:3459-3470, American Chemical Society (March 2004)	i he
	,	•	
			,.
			٠,.
		-	+ -
			-

491513_1.DOC

I	Examiner	Date	
ı	Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Application form to the uspect of the depending upon the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.